DTC 검사 시장 규모, 점유율 및 동향 분석 보고서 : 검사 유형별, 검체 유형별, 최종 용도별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

Direct-to-Consumer Testing Market Summary

The global direct-to-consumer testing market size was estimated at USD 4.70 billion in 2025 and is projected to reach USD 16.05 billion by 2033, growingat a CAGR of 14.51% from 2026 to 2033. This growth is driven by the rising prevalence of chronic diseases, an increasing emphasis on preventive and personalized healthcare, and ongoing technological advancements in diagnostics and testing.

In addition, the convenience and accessibility of at-home testing are further accelerating market demand. Moreover, expanding applications across genetic testing, nutrition, and disease risk assessment are enhancing the overall value proposition. As a result, the direct-to-consumer testing market is evolving into a key component of consumer-driven healthcare, with strong growth potential across both developed and emerging regions.

The growth of the direct-to-consumer testing market is driven by the rising prevalence of chronic diseases. Chronic conditions require continuous monitoring, creating a strong demand for accessible diagnostic solutions that patients can use at home. According to the World Health Organization, non-communicable diseases account for over 74% of global deaths, underscoring the need for early detection and preventive care. direct-to-consumer testing enables individuals to assess genetic predisposition to conditions such as BRCA-related breast cancer, heart disease, and metabolic disorders, facilitating timely lifestyle modifications and medical intervention This trend is accelerating the adoption of accessible, at-home diagnostic tools and reinforcing the role of direct-to-consumer testing in preventive healthcare.

Global Direct-to-Consumer Testing Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the direct-to-consumer testing market report on the basis of test type, sample type, end use, distribution channel, and region:

• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• Genetic Testing
• Infectious Disease
• Allergy Testing
• Hormone & Fertility
• Cardiovascular Health
• Nutrition & Wellness
• Others
• Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
• Blood
• Saliva/Buccal Swab
• Urine
• Hair/Nails
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Individual Consumers
• Corporate Wellness
• Pharmacies & Retail
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Online / D2C Platforms
• Pharmacies & Drug Stores
• Hospitals & Clinics
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Test Type
  • 1.2.2. Sample Type
  • 1.2.3. End Use
  • 1.2.4. Distribution Channel
  • 1.2.5. Regional Scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Direct-to-Consumer Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of chronic diseases,
    • 3.2.1.2. Increasing emphasis on preventive and personalized healthcare.
    • 3.2.1.3. Ongoing technological advancements in diagnostics and testing
    • 3.2.1.4. The convenience and accessibility of at-home testing
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Regulatory challenges and accuracy concerns
    • 3.2.2.2. Limited awareness, cost, and accessibility
• 3.3. Direct-to-Consumer Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Direct-to-Consumer Testing Market: Test Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Direct-to-Consumer Testing Market: Test Type Movement Analysis
• 4.3. Direct-to-Consumer Testing Market by Test Type Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Genetic Testing
  • 4.5.1. Genetic Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Infectious Disease
  • 4.6.1. Infectious Disease Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Allergy Testing
  • 4.7.1. Allergy Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Hormone & Fertility
  • 4.8.1. Hormone & Fertility Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.9. Cardiovascular Health
  • 4.9.1. Cardiovascular Health Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.10. Nutrition & Wellness
  • 4.10.1. Nutrition & Wellness Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.11. Others
  • 4.11.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Direct-to-Consumer Testing Market: Sample Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Direct-to-Consumer Testing Market: Sample Type Movement Analysis
• 5.3. Direct-to-Consumer Testing Market by Sample Type Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Blood
  • 5.5.1. Blood Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Saliva/Buccal Swab
  • 5.6.1. Saliva/Buccal Swab Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Urine
  • 5.7.1. Urine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Hair/Nails
  • 5.8.1. Hair/Nails Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Direct-to-Consumer Testing Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Direct-to-Consumer Testing Market: End Use Movement Analysis
• 6.3. Direct-to-Consumer Testing Market by End Use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Individual Consumers
  • 6.5.1. Individual Consumers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Corporate Wellness
  • 6.6.1. Corporate Wellness Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Pharmacies & Retail
  • 6.7.1. Pharmacies & Retail Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Direct-to-Consumer Testing Market: Distribution Estimates & Trend Analysis

• 7.1. Online / D2C Platforms
• 7.2. Online / D2C Platforms Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.3. Pharmacies & Drug Stores
• 7.4. Pharmacies & Drug Stores Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Hospitals & Clinics
• 7.6. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Others
• 7.8. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Direct-to-Consumer Testing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.9. Rest of Europe
    • 8.4.9.1. Key country dynamics
    • 8.4.9.2. Regulatory framework/ reimbursement structure
    • 8.4.9.3. Competitive scenario
    • 8.4.9.4. Rest of Europe market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.7. Rest of Asia Pacific
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework/ reimbursement structure
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Rest of Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. Rest of Latin America
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Rest of Latin America market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.5. Rest of MEA
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Rest of MEA market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Recent Developments & Impact Analysis by Key Market Participants
• 9.3. Company Market Share Analysis, 2025
• 9.4. Key Company Profiles
  • 9.4.1. 23andMe
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Test Type benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. AncestryDNA
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Test Type benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. MyHeritage Ltd
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Test Type benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Gene by Gene, Ltd
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Test Type benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Living DNA Ltd
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Test Type benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Color Health Inc
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Test Type benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. CircleDNA
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Test Type benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Dante Labs
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Test Type benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Helix, Inc.
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Test Type benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Mapmygenome
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Test Type benchmarking
    • 9.4.10.4. Strategic initiatives